arrow
R

Ronald D. Perrone

university of chicago
H指数:56
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression

一项个体患者Meta分析评估了慢性肾病进展的随机对照试验中,白蛋白尿变化与肾小球滤过率急性变化之间的关联

2026-09-300
PRE
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure

白蛋白尿作为终末期肾病替代终点的荟萃分析

2025-11-060
PRE
Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development (EL-PFDD) Concepts for Autosomal Recessive Polycystic Kidney Disease (ARPKD) Against SONG Initiatives

对常染色体隐性多囊肾病(ARPKD)的对外驱动患者聚焦药物开发(EL-PFDD)概念进行定性分析与比较,并与SONG倡议进行对比。

2025-09-170
OAAI
Validating the SONG-PKD Pain Instrument , a Core Outcome Measure for Pain in ADPKD
2025-02-010
OAAI
Effect of Dual RAAS Blockade and Intensive BP Lowering on Risk of End- Stage Kidney Disease and Death in Autosomal Dominant Polycystic Kidney Disease: Long-term Follow-up of the HALT-PKD Trials

双RAAS阻断联合强化降压对常染色体显性多囊肾病终末期肾病和死亡风险的影响:HALT-PKD试验的长期随访

2025-01-011
PRE
A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection

急性治疗对肾小球滤过率的影响对长期肾脏保护的随机对照临床试验的荟萃分析

2024-10-011
PRE
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

GFR斜率作为肾衰竭替代终点的荟萃分析

2023-06-1745
PRE
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial
2023-05-016
OA